Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to Strong-Buy at Truist Financial

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by Truist Financial to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

COLL has been the subject of a number of other research reports. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Needham & Company LLC restated a “buy” rating and issued a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Finally, Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $34.19 on Monday. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. The company has a market cap of $1.11 billion, a price-to-earnings ratio of 16.76 and a beta of 0.75. The stock’s 50-day moving average is $34.03 and its two-hundred day moving average is $40.42. Collegium Pharmaceutical has a 1-year low of $29.11 and a 1-year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The business had revenue of $193.52 million during the quarter, compared to analysts’ expectations of $184.47 million. During the same quarter last year, the business posted $1.49 EPS. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. Analysts forecast that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP David Dieter sold 13,976 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the completion of the transaction, the executive vice president directly owned 77,071 shares of the company’s stock, valued at $2,691,319.32. This represents a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.85% of the stock is owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its holdings in shares of Collegium Pharmaceutical by 59.1% in the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after buying an additional 538,337 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Collegium Pharmaceutical by 65.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after acquiring an additional 518,721 shares in the last quarter. Millennium Management LLC raised its stake in Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Collegium Pharmaceutical by 161.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock valued at $23,692,000 after acquiring an additional 316,109 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in Collegium Pharmaceutical by 897.2% in the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after acquiring an additional 242,310 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.